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The electrophysiologic effects of oral encainide (75 to 150 
mg daily) were evaluated in 14 patients (6 male and 8 
female, aged 49 + 9 years) with atrioventricular (AV) node 
reentrant tachycardia of the slow-fast type. The patients 
were studied in control conditions and after 2 to 12 days of 
treatment. 
mean plasma concentrations of encainide and its metabolites 
0-demethyl-encainide and 3.methoxy-O-demethyl-encainide 
measured in 13 patients during the repeat study were 161 2 
304, 128 -C 100 and 95 f 85 ng/ml, respectively; three poor 
metabolizers who presented a high concentration of the 
parent compound were observed in this series. 
Encainide increased the AH interval from 67 f 10 to 82 
f 23 ms (p < 0.02). Anterograde Wenckebach cycle length 
was increased in three patients, reduced in four, unchanged 
in one; it was not measurable in the remaining patients 
because tachycardia was induced. Retrograde Wenckebach 
periodicity increased from 307 f 71 to 401 f 92 ms (p < 
0.005) in all nine patients in whom it was measurable; 
complete retrograde block was observed in one patient. At 
the control study, tachycardia was induced in ail patients, 
with a mean cycle length of 341 f 50 ms; after encainide, 
tachycardia was inducible in only 1 patient, with an increase 
in cycle length from 270 to 320 ms; in the other patients, 
tachycardia was not inducible because of a lack of retrograde 
(11 patients) or anterograde (2 patients) conduction. The 
All patients were discharged on encainide at a mean 
daily dose of 112 f 39 mg. One patient dropped out of the 
study 1 month later because of neurologic side effects 
(blurred vision and vertigo). During a mean follow-up 
period of 24 f 11 months, nine patients are completely free 
of attacks, three patients had only one recurrence and one 
patient had a marked reduction of attacks; no one com- 
plained of side effects. 
Encainide appears to be highly effective in preventing AV 
node reentrant tachycardia, mainly by depressing conduc- 
tion in the retrograde limb of the reentrant circuit. The drug 
demonstrates long-term clinical efficacy and does not induce 
any significant side effect at the doses used in this trial. 
(J Am Co11 Cardiol1989;14:992-8) 
Encainide is a class IC antiarrhythmic drug (1) that has been 
recently introduced in clinical use for treatment of ventricular 
arrhythmias. As an investigational drug, it was also shown to 
be highly effective in the treatment of supraventricular ar- 
rhythmias, particularly when involving an accessory atrioven- 
tricular (AV) pathway (2-5). In contrast, little information is 
yet available on its usefulness in paroxysmal AV node reen- 
trant tachycardia, in which the reentrant loop is confined to 
the AV node and utilizes a “slow” pathway in the antero- 
grade direction and a “fast” pathway in the retrograde 
direction. Because encainide has been demonstrated to de- 
press conduction both in fast sodium channel-dependent 
fibers as well as in slow channel-dependent fibers, particularly 
when given orally (5-7), it was postulated that the drug should 
be effective in AV node reentrant tachycardia in which the 
mechanism appears to involve both types of fibers. 
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The aims of the present study were: 1) to demonstrate the 
effectiveness of oral encainide in preventing AV node reen- 
trant tachycardia electrically induced during electrophysio- 
logic study; and 2) to establish the clinical usefulness and 
safety of the drug during a prolonged follow-up period. 
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Methods 
Study patients (Table 1). The study group consisted of 14 
patients (6 male and 8 female) with recurrent paroxysms of 
AV node reentrant tachycardia. Their ages ranged from 34 to 
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Table 1. Clinical Characteristics of 14 Patients 
Duration of No. of 
Patient Age (yr) Frequency Symptoms Previous 
No. & Gender ECG Diagnosis of SVT Symptoms (yr) Drugs Used 
I 53M SVT (160 beatsimin) l/week Palpitation 3 I 
2 55F SVT (180 beatsimin) l/day Palpitation 40 6 
3 57M SVT (150 beatsimin). l/month Palpitation. chest pain I2 I 
previous MI 
4 34M SVT (240 beatsimin) 3imonth Palpitation II I 
5 46F SVT (210 beatsimin) l/month Palpitation 24 5 
6 63M SVT (180 beatsimin). l/week Palpitation. chest pain 4 1 
previous MI 
7 59M SVT (170 beatsimin) l/month Palpitation 4 3 
8 48F SVT (180 beatsimin) l/month Palpitation 20 2 
9 39F SVT (150 beatsimin) l/month Palpitation 20 3 
IO 53M SVT (190 beatsimin) 112 months Palpitation. dizziness 1 I 
II 56F SVT (180 beatsimin) Ii? months Palpitation 20 2 
12 43F SVT (170 beatsimin). I/month Palpitation I3 2 
VPE 
I3 38F SVT (170 beatsimin) ?/month Palpitation. dizziness IO 2 
14 39F SVT (220 beatsimin) l/month Palpitation. dizziness 27 1 
ECG = electrocardiographic; F == female; M = male: MI = myocardial infarction: SVT = supraventricular tachycardia; VPE = ventricular pre-excitation. 
63 years (mean t S.D. 49 lr 9). During sinus rhythm, only 
one patient (Case 12) showed electrocardiographic (ECG) 
evidence of the Wolff-Parkinson-White pattern, but this 
patient was included in this group because the accessory 
pathway was shown not to be involved in the reentrant 
mechanism. All patients underwent clinical, radiographic 
and echocardiographic examinations that revealed cardiac 
abnormalities in only two patients (Cases 3 and 6) who had 
signs of previous myocardial infarction. These two patients 
complained of angina pectoris during tachycardia; in Case 6, 
coronary artery bypass operation was performed 1 year 
before entry to this study, which eliminated the angina, but 
did not influence the number of paroxysms of tachycardia. 
No patient had evidence of renal or hepatic dysfunction. 
Basal electrophysiologic study. All patients enrolled gave 
their informed written consent; the study protocol was 
approved by the institution’s Ethical Committee on Human 
Research. The electrophysiologic studies were performed in 
the postabsorptive and nonsedated state. Before the studies. 
any previous drug treatment was stopped for at least 5 
elimination half-lives. For the control study, four multipolar 
electrode catheters were introduced percutaneously under 
local anesthesia and positioned under fluoroscopic control in 
the high lateral right atrium. left atrium (through the coro- 
nary sinus), apex of the right ventricle and His bundle 
region, and were used for recording and stimulation. Four 
surface ECG leads (I, III, V, and V,) and all intracardiac 
electrograms were displayed simultaneously on a multichan- 
nel oscilloscope and recorded at paper speeds of 50 to 100 
mm/s. Electrical stimulation was provided with a program- 
mable stimulator (Cardiovascular Instruments model 4279). 
using rectangular impulses with a duration of 2 ms at twice 
diastolic threshold. 
The stimulation protocol included: incremental atria1 pac- 
ing, single atria1 premature beats during atria1 pacing, incre- 
mental ventricular pacing, single ventricular premature beats 
during ventricular pacing and atria1 or ventricular extrastim- 
ulus and overdrive pacing, or both, during tachycardia. 
Previously reported conventional criteria (8) were utilized to 
identify the exact mechanism of tachycardia, particularly to 
exclude the participation of an accessory AV pathway as the 
retrograde limb of the circuit. 
Encainide study. At the end of the control electrophysi- 
ologic study, the first seven patients were given oral encain- 
ide in a dosage of 50 mg every 8 h. After observing the 
favorable results obtained with this dosage, it was decided to 
verify in the remaining patients (Cases 8 to 14) whether the 
same effectiveness could be achieved with a dose of 25 mg 
every 8 h. After 2 to 12 days (mean 5 + 3) of this regimen, 
electrophysiologic study was repeated 1 to 2 h after an oral 
dose, using the same technique and the same stimulation 
protocol (the catheter in the coronary sinus was not utilized 
in the repeat study). A heparinized blood sample for evalu- 
ation of drug concentration was drawn at the beginning of 
stimulation; concentrations of encainide and its active me- 
tabolites 0-demethyl-encainide and 3-methoxy-O-demethyl- 
encainide were determined by high performance liquid chro- 
matography (9). 
Follow-up. All patients were discharged on encainide 
therapy at the daily dose tested during electrophysiologic 
study and independently of its results. The patients were 
observed monthly for the initial 3 months and at 3 month 
994 CHIMIENTI ET AL. 
ENCAINIDE IN ATRIOVENTRICULAR NODE TACHYCARDIA 
JACC Vol. 14, No. 4 
October 1989992-8 
Table 2. Overall Effects of Encainide on Basic Electrophysiologic and ECG Variables 
in 14 Patients 
75 mgiday (Cases 8 to 14) 150 mgiday (Cases I to 7) 
Control Encainide Control Encainide 
Sinus cycle length 701 2 96 784 + 59 754 % 130 761 + 115 
PA interval 40.0 % 5.8 46.4 + 8.5 38.6 It 7.5 44.2 2 Il.]* 
AH interval 62.5 + 7.6 75.0 ? 18.7 71.7 * 10.3 88.3 + 26.2 
HV interval 37.5 + 7.6 40.0 ? 9.5 42.5 + 6.9 51.7 + 10.8* 
Atria1 ERP 210 * 30 218 ? 26 189 ‘- 19 230 2 40* 
Ventricular ERP 225 2 14 243 + 23 227 ? 34 250 ‘- 27 
PR interval 137 * 14 151 * II* 163 f 14 171 ? 20 
QRS duration 84 ? 5 90 ? 8 87 + 9 96 f 5* 
QTc interval 393 + 19 418 * 38 394 + 23 426 ? 30t 
*p < 0.05; tp < 0.01. All values are expressed in ms. ERP = effective refractory period; QTc interval = 
corrected QT intkrval. 
intervals thereafter; they were carefully questioned about 
symptoms and side effects and underwent physical exami- 
nation, 12 lead ECG, standard blood chemistry screening 
and ambulatory ECG recording. 
Statistical analysis. Results are presented as the mean 
value k SD. Student’s t test for paired data was used, when 
indicated, to determine probable differences; a p value CO.05 
was regarded as significant. 
Results 
Electrophysiologic effects (Table 2). No patient reported 
any side effects while in the hospital; all the studies were 
carried out without complications. The electrophysiologic 
data in Table 2 are considered separately according to the 
dose used (75 versus 150 mg daily). The findings are in 
accordance with those previously reported (2-7) and confirm 
a modest increase in both conduction and refractoriness 
variables induced by the drug. It is noteworthy that in this 
group of patients with AV node reentrant tachycardia, 
anterograde conduction velocity through the AV node, as 
measured by AH interval duration, is decreased by the drug 
at both doses. In the entire group of patients, AH interval 
increased from 67 + 10 to 82 k 23 ms (mean 15 + 18; range 
0 to 50) (p < 0.02). The drug also induced only a slight 
increase in ECG intervals; in particular, QRS duration, the 
increase of which is usually considered a measure of toxic 
effects, did not increase significantly in this group of pa- 
tients, probably because of the mean low dosage employed. 
Drug effects on tachycardia (Table 3). Because antero- 
grade and retrograde conduction and refractoriness of the 
AV node are involved in the mechanism of induction and 
Table 3. Effects of Encainide on Variables Involved in the Mechanism of Tachycardia in 14 Patients 
Patient 
No. 
Encainide 
Daily Dose 
Tested 
(mg) 
Anterograde Retrograde 
AVN-ERP VACS-ERP 
C E C E 
Anterograde 
Wenckebach 
Point 
C E 
Retrograde 
Wenckebach Point 
C E 
AVNRT Cycle 
Length 
(site of block) 
C E 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
I50 cl80 
150 260 
150 320 
150 250 
150 <220 
150 230 
150 <240 
75 <260 
75 290 
75 <230 
75 <220 
75 <260 
75 270 
75 180 
~250 
360 
~270 
<210 
~230 
260 
260 
310 
<240 
<240 
~270 
270 
<210 
~270 490 360 360 340 580 
~230 Block 270 400 230 Block 
<260 <290 400 380 460 500 
<240 ~230 NA 320 NA NA 
1200 ~260 250 240 240 330 
<280 ~250 260 300 240 310 
1200 340 350 300 250 380 
<240 <250 NA 400 270 320 
NA NA NA 420 NA NA 
260 1250 280 310 320 410 
<230 220 NA 380 290 340 
1230 ~290 NA 400 NA 350 
<230 <230 360 350 350 440 
<220 490 NA 400 NA 450 
370 NI (fast) 
330 NI (fast) 
460 NI (fast) 
270 320 
300 NI (fast) 
340 NI (fast) 
350 NI (fast) 
330 NI (slow) 
400 NI (fast) 
320 NI (fast) 
330 Nl (slow) 
350 NI (fast) 
360 NI (fast) 
260 NI (fast) 
All values are expressed in milliseconds. AVN = atrioventricular node; AVNRT = atrioventricular node reciprocating tachycardia; C = control study; E = 
encainide study; ERP = effective refractory period: NA = not available; NI = not induced; VACS = ventriculoatrial conduction system. 
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Figure 1. Patient 9. Prevention of induction 
of AV node reentrant tachycardia by oral 
encainide (75 mg daily). A, After an atrial 
drive train (Al) of 600 ms, sustained tachy- 
cardia is induced by a premature atrial stimu- 
lus at a coupling interval (Al-A2) of 450 ms. 
B, During oral treatment with encainide, 
tachycardia is not inducible by atrial prema- 
ture stimulation at any coupling interval be- 
cause of block in the retrograde limb of the 
reentrant circuit. In the top panel of B, at a 
coupling interval of 290 ms, A2 is slowly 
conducted to the His bundle (H2), but no echo 
beat is recorded; at a shorter coupling interval 
(280 ms, bottom panel) the AV node is refrac- 
tory. Each panel shows ECG leads I, III and 
V, and intracardiac recordings from the high 
right atrium (HRA) and His bundle (His). 
interruption of AV node reciprocating tachycardia, the 
A “’ 
HRA 
HIS 
HRA 
HIS 
B 
I 
III 
“1 
CONTROL 
b L L 
ENCAI NIDE 
A - 
A - 
HRI 
changes induced by oral encainide on these variables were 
analyzed. Both anterograde AV node and retrograde con- 
duction system effective refractory periods could not always 
be measured because they were limited by atria1 and ven- 
tricular refractoriness, so statistical analysis of the data was 
not performed. By considering only the patients whose data 
could be compared, at least qualitatively, the drug increased 
anterograde AV node refractoriness in four of seven patients 
and retrograde conduction system effective refractory period 
in five of six patients; in one of the latter patients, retrograde 
conduction block was observed at the repeat study. The 
anterograde Wenckebach cycle length was not measurable in 
six patients at the control study because of the induction of 
tachycardia. In the remaining patients, this variable was 
either increased (three patients) or reduced (four patients) 
and in one patient it was unchanged. The retrograde Wenck- 
ebach periodicity was not identified in 3 of 13 patients (in 
Case 9, ventricular stimulation was not performed) because 
of tachycardia onset in the control study. In all other 
patients, this variable increased by 40 to 240 ms; the mean 
value increased significantly from 307 2 71 to 401 t 92 ms 
(p < 0.005). 
In all patients, tachycardia was repeatedly induced with 
electrical stimulation during control study. A clear dual AV 
node pathway conduction pattern, identified by a discontin- 
uous response of AV node conduction time to progressively 
premature stimuli, was demonstrated in eight patients. A 
paroxysm of tachycardia started every time anterograde 
conduction jumped through the slower pathway. Tachycar- 
dia mean cycle length was 341 + 50 ms. In the repeat study 
on drug therapy, tachycardia could not be induced with any 
technique of atria1 and ventricular stimulation except in one 
patient (Case 4), in whom tachycardia cycle length increased 
from 270 to 320 ms. In 11 patients, tachycardia was not 
inducible with atria1 premature stimulation because of the 
lack of conduction in the retrograde limb of the circuit (Fig. 
I), whereas in the remaining 2 patients one or two echo beats 
were not followed by anterograde conduction. In Case 2. 
complete retrograde dissociation was demonstrated in the 
repeat study. 
Drug plasma levels (Table 4). In 13 of the 14 patients, the 
drug concentrations of encainide and of its two metabolites 
(0-demethyl-encainide and 3- methoxy-O-demethylencain- 
ide) at the time of stimulation during repeat study were 
available. The mean values were 161 L 304, 128 * 100 and 
95 t 85 ngiml, respectively. Three of these patients (Cases 6, 
8 and 13) considered “poor metabolizers” are included in 
this series; encainide plasma concentration was particularly 
high in these three patients (990, 226 and 638 ng/ml, respec- 
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Table 4. Plasma Concentrations of Encainide and Its Metabolites 
in 14 Patients 
Daily Dose Plasma Concentration 
Patient Tested 
No. (mg) Encainide ODE MODE 
1 I50 65 256 101 
2 150 NA NA NA 
3 150 32 135 58 
4 150 9 189 128 
5 150 30 150 89 
6 150 990 0 0 
7 150 0 150 155 
8 75 226 0 0 
9 15 32 113 63 
10 75 10 58 70 
11 75 0 68 88 
12 15 61 328 184 
13 75 638 16 0 
14 75 0 204 303 
All values are expressed in &ml. MODE = 3-methoxy-O-demethyl- 
encainide; NA = not available; ODE = 0-demethyl-encainide. 
tively), although the metabolites were not detectable (or 
were present at a very low level, as in Case 13) at the time of 
study. 
Follow-up. All patients were discharged on encainide 
therapy at the same dose tested while they were in the 
hospital, including Patient 4, who was the only patient to 
have the tachycardia induced during electrophysiologic 
study after administration of encainide. The mean mainte- 
nance dose was 112 ? 39 mg daily. Patient 8, who was one 
of the poor metabolizers of this series, complained of blurred 
vision and mild vertigo a few days after discharge; she 
refused a dose reduction and was definitively dropped from 
the study 1 month later. At that time, no information was yet 
available about her drug and metabolite plasma concentra- 
tions. The remaining 13 patients were followed up for 10 to 
44 months (mean 24 ? 11); none complained of any side 
effects during the follow-up period. All but four patients 
were completely free of attacks; Patients 3, 6 and 7 had only 
one episode each during the prolonged period of treatment 
(26, 18 and 16 months, respectively). The paroxysms were 
better tolerated, of shorter duration and never required 
hospitalization. Finally, only Patient 2, who had a history 
characterized by a mean of one episode daily despite previ- 
ous treatments, continued to report a mean of one episode 
monthly, interrupted with vagal stimulation maneuvers. 
Discussion 
Effects of encainide on tachycardia. Repeat electrophysi- 
ologic studies during treatment have been utilized for many 
years in patients with various types of tachycardias to 
predict the clinical efficacy of antiarrhythmic drugs. In 
patients with paroxysmal AV node reentrant tachycardia, 
previous studies have reported on the antiarrhythmic activ- 
ity of several drugs, such as propranolol (lo), ouabain (1 l), 
verapamil (12), procainamide (13), quinidine (14), disopyra- 
mide (15) and flecainide (16). 
Paroxysmal AV node reentrant tachycardia is sustained 
by a reentrant mechanism confined to the AV node region. 
The anterograde limb of the circuit is composed of the AV 
node (or part of it) (that is, by slow conducting fibers 
particularly sensitive to calcium channel antagonists, digi- 
talis or beta-adrenergic blockers). In contrast, the retrograde 
limb is composed of a nodal (or paranodal of the James fibers 
type) structure characterized by fast conduction. This struc- 
ture is, thus, sensitive to antiarrhythmic agents of the class I 
or III type. 
Drugs further decreasing the slow anterograde nodal 
conduction are commonly utilized to interrupt a paroxysm of 
AV node reentrant tachycardia. Paradoxically, such drugs 
not only are often ineffective in preventing recurrences of 
tachycardia, but also may increase recurrences because 
slower conduction of premature atria1 beats may favor 
reentry of the impulse to the atria. The ideal antiarrhythmic 
agent to prevent AV node reentrant tachycardia should, 
therefore, exert a double activity. On the one hand, it should 
depress slow channel-dependent anterograde AV node con- 
duction to decrease the rate and possibly interrupt the 
tachycardia. At the same time, the drug should also decrease 
conduction in the fast sodium channel-dependent fibers 
involved in the retrograde limb of the loop to prevent reentry 
of slowly conducted beats. Encainide seems to have both 
these properties, as amply demonstrated in previously re- 
ported studies (2-6). The drug was demonstrated to be very 
active in preventing induction of supraventricular tachycar- 
dias sustained by reentry involving an accessory AV path- 
way in retrograde direction (2-5). Only sporadically has the 
drug activity been evaluated in patients with AV node 
reentrant tachycardia. Miles et al. (17) demonstrated antiar- 
rhythmic efficacy of encainide in two of three patients with 
this type of tachycardia. 
In our series, encainide demonstrated excellent activity in 
preventing electrically inducible AV node reentrant tachy- 
cardia. In all but one patient, tachycardia could no longer be 
induced on treatment, even at the lower dose tested (75 mg 
daily). It is noteworthy that in 10 of 13 patients, tachycardia 
was not induced because of the lack of conduction in the 
retrograde pathway. The greater activity of the drug on the 
fast sodium channel-dependent structure was also demon- 
strated by the overall greater effects on the shortest cycle 
length with 1: 1 conduction in retrograde direction compared 
with the anterograde direction, which is more widely influ- 
enced by autonomic tone changes. This prevalent effect on 
retrograde fast pathway conduction was also demonstrated 
in patients treated with procainamide (13), quinidine (14), 
disopyramide (15) and flecainide (16). 
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Electrophysiologic effects. The effects of encainide on the 
principal electrophysiologic and ECG variables observed in 
this study are similar to those previously reported (6). It 
should be noted that a lesser increase of these variables was 
observed in this study (Table 2) because of the lower doses 
utilized (75 and 150 mg daily versus a mean of 242 mg daily 
in the study performed by Jackman et al. [61). The most 
impressive effect of encainide was observed on retrograde 
conduction, which was depressed in all patients. In the eight 
patients in whom anterograde and retrograde Wenckebach 
cycle lengths could be compared. the drug exerted a greater 
effect on retrograde conduction. In contrast, no significant 
difference was evident between the effects of the lower 
compared with the higher dose. 
Encainide plasma concentrations. In our group of pa- 
tients, plasma concentrations of encainide and its metabo- 
lites showed great interindividual variability. Moreover. no 
clear correlation was evident between plasma levels of the 
drug or its metabolites and electrophysiologic activity. It is 
believed that approximately 10% of the population is genet- 
ically unable to metabolize the drug (18). Three poor metab- 
olizers were present in our series; plasma concentrations of 
encainide at the time of study were particularly high in these 
patients, but no clear difference was demonstrated in the 
electrophysiologic behavior of these patients compared with 
the others. It is of interest that one of the poor metabolizers 
was the only patient to develop mild side effects a few days 
after discharge when blood concentration of encainide was 
much higher than the mean. 
Clinical effects. The clinical antiarrhythmic efficacy of 
encainide was widely demonstrated during a prolonged 
follow-up period. With the exception of one patient, all were 
virtually completely protected by this treatment, even at a 
mean maintenance dose that was particularly low. In a 
previous series of patients with the Wolff-Parkinson-White 
syndrome (5). the mean maintenance dose able to prevent 
recurrences of tachyarrhythmias in most of the patients was 
also very low (127 mg daily), much lower than the doses 
reported by others in patients with supraventricular tachy- 
cardias: 197 mg daily (2) and 175 mg daily (3). This finding 
confirms that, at least in paroxysmal supraventricular tachy- 
cardia. encainide is highly effective at doses of ~150 mg 
daily. In this way, the incidence of side effects is very low. 
The very low number of recurrences observed during 
treatment in both laboratory and clinical settings makes 
prediction of clinical outcome on the basis of laboratory tests 
very difficult. It is impossible to evaluate sensitivity and 
specificity of the laboratory test. It also must be kept in mind 
that the drug suppresses ectopic activity, the trigger in most 
supraventricular tachycardias, and this may be another 
mechanism of prevention of clinical tachycardias. In any 
case, it should be emphasized that the only patient who had 
recurrences at the repeat electrophysiologic study was com- 
pletely free of attacks during the follow-up period, and the 
only patient who had more than one recurrence during 
follow-up period had the highest number of attacks and 
previous treatment failures by history. 
Conclusions. The present study demonstrates that oral 
encainide. even at a low dose of 75 mg daily, prevents 
laboratory induction of AV node reentrant tachycardia 
mainly by depressing conduction over the retrograde limb of 
the reentrant circuit. Drug efficacy was confirmed during 
clinical use by suppressing recurrences in the great majority 
of patients treated. When utilized at a low dose, the drug is 
safe and well tolerated in most patients. 
We are grateful to Bristol-Myers Company for supplying the drug and to 
Professor R. Shanks (Department of Therapeutics and Pharmacology, The 
Queen’s University, Belfast, Northern Ireland) for performing analyses of the 
plasma concentrations of the drug. 
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